| Document |
Document Title |
|
WO/2024/089634A1 |
The present disclosure relates to compositions comprising RNA molecules encoding an antigen derived from influenza, wherein the RNA is formulated in a lipid nanoparticle (LNP), and wherein the composition further includes a polypeptide a...
|
|
WO/2024/088435A1 |
Provided is a Pseudomonas sp. having a mutant of PHA polymerase PhaC61-3. The Pseudomonas sp. is fermented to produce a novel viscous polyhydroxyalkanoate, providing a new material for the preparation of degradable products.
|
|
WO/2024/087515A1 |
Provided are an anti-CD16A antibody and an application thereof. The antibody comprises heavy chain variable region CDR1, CDR2 and CDR3 sequences as shown in SEQ ID NOs: 1, 2 and 3 respectively, or amino acid sequences at least 95% identi...
|
|
WO/2024/090383A1 |
Provided is a production method of cells into which exogenous mitochondria have been introduced, the production method comprising culturing recipient cells using cell culture equipment in which mitochondria isolated from donor cells are ...
|
|
WO/2024/092258A2 |
Disclosed herein are novel transcription factors for promoting reprogramming of, and/or for direct conversion of, an astrocyte to a neuron. Further provided are polynucleotides encoding the transcription factors, as well as DNA targeting...
|
|
WO/2024/090872A1 |
The present invention relates to a method and a kit for rapidly diagnosing tsutsugamushi on the basis of genetic scissors. More specifically, the present invention relates: to a molecular diagnosis method for rapidly detecting Orientia t...
|
|
WO/2024/088325A1 |
The present invention relates to an antibody that specifically binds to CLDN6, and the use thereof.
|
|
WO/2023/056252A9 |
Multispecific binding proteins that bind NKG2D receptor, CD 16, and B cell-activating factor receptor (BAFF-R) are described, as well as pharmaceutical compositions and therapeutic methods of the multispecific binding proteins useful for...
|
|
WO/2024/092217A1 |
The present disclosure provides systems and methods for high throughput genetic manipulation. Particularly, systems and methods are provided for scalable gene insertions in mammalian cells, the systems and methods comprise a donor nuclei...
|
|
WO/2024/088808A1 |
Provided are compositions containing microalgae extracellular vesicles (MEVs) formulated for intranasal delivery, whereby, upon intranasal administration the MEVs traffic through specific routes following intranasal administration to spe...
|
|
WO/2024/086919A1 |
The present disclosure provides antibodies or antigen-binding fragments thereof that bind specifically to integrin α11 (ITGA11). This disclosure also provides methods for treating a disorder in a subject, such as a fibrotic disorder, an...
|
|
WO/2024/090884A1 |
The present invention relates to a novel phenylalanine:H+ symporter PheP variant and a method for producing L-aromatic amino acids using same, wherein the protein activity of the phenylalanine:H+ symporter PheP variant changes as at leas...
|
|
WO/2024/092095A1 |
Provided herein are methods and compositions for the diagnosis, prognosis, and treatment of a vascular disease, such as coronary artery disease (CAD), in a subject. In particular, provided are methods and compositions for treating a vasc...
|
|
WO/2024/090455A1 |
A multiple sclerosis diagnostic method according to the present invention comprises: a step for measuring the relative abundance of a bacterium contained in a saliva sample collected from a subject; and a step for performing (1) or (2) b...
|
|
WO/2024/091909A1 |
Described are methods of inducing a protective immune response against Lassa virus comprising administering a prophylactically effective amount of a nucleic acid molecule encoding a Lassa virus glycoprotein precursor (LASV GPC) to a subj...
|
|
WO/2024/090415A1 |
The present invention addresses the problem of providing lactic acid bacteria having high ability to activate innate immunity. The present invention also addresses the problem of providing: an innate immunity activator containing, as an ...
|
|
WO/2024/088371A1 |
An isolated antigen-binding protein capable of targeting MSLN. The isolated antigen-binding protein comprises at least one CDR in an antibody heavy chain variable region VH, and the VH comprises an amino acid sequence represented by any ...
|
|
WO/2024/090563A1 |
The purpose of the present invention is to provide: a nucleic acid for gene expression uses, which can amplify a conditional gene expression vector stably, can be used in a gene expression analysis in a wide variety of organism species a...
|
|
WO/2024/088412A1 |
Disclosed are a TLR7-IFN I signaling pathway activated mouse in-vivo cell, a humanized systemic lupus erythematosus mouse having the cell, a construction method for the mouse, and a use of the mouse in medical research. Specifically, a T...
|
|
WO/2024/088175A1 |
Disclosed in the present disclosure are a gRNA targeting VEGFA, a gene editing system, and the use thereof. The gRNA in the present disclosure comprises a guide sequence which has at least 80% sequence identity to any one of SEQ ID NOs: ...
|
|
WO/2024/086899A1 |
The present disclosure relates to a method of separation of charged substances by electrophoresis by using an inorganic thread. It includes contacting an electrolyte with an outer surface of the inorganic thread to cause wetting the oute...
|
|
WO/2024/090441A1 |
The purpose of the present invention is to provide single-round infectious particles that are derived from a virus belonging to the orthocoronavirus subfamily and in which not only the spike (S) protein on the surface of the virus belong...
|
|
WO/2024/091874A1 |
Disclosed herein are compositions comprising a MTRES1 gene therapy. Also provided herein are methods of treating conditions associated with MTRES1 gene mutations that include providing a MTRES1 gene therapy.
|
|
WO/2024/091990A1 |
Described are methods of treating human papillomavirus (HPV) type 16- or HPV type 18-related High-grade Squamous Intraepithelial Lesion (HSIL) of the cervix. The described methods comprise evaluating one or more biological samples for th...
|
|
WO/2024/092186A2 |
Described genetically modified Fragaria plants having increased resistance to anthracnose fruit rot. Compositions for modifying Fragaria plants to increase resistance to anthracnose fruit rot and methods of using the compositions to modi...
|
|
WO/2024/088051A1 |
The present invention relates to the field of biotechnology, and provides a cell wall synthesis-related protein UGMA, a gene encoding same, and a use thereof. The use of the cell wall synthesis-related protein UGMA or the gene encoding t...
|
|
WO/2024/087784A1 |
The present invention belongs to the technical field of genetic engineering and synthetic biology. Provided are a recombinant type XVII humanized collagen expressed in yeast and a preparation method therefor, and particularly provided ar...
|
|
WO/2024/090815A1 |
The present invention relates to a technology for producing human papillomavirus virus-like particles from a plant and, more specifically, to a technology for effectively producing human papillomavirus virus-like particles in a plant chl...
|
|
WO/2024/088396A1 |
Provided are an FNR mutant and the use thereof in gene expression regulation. The mutant has an R169G and/or a G216D mutation on the amino acid sequence of the FNR, and the amino acid sequence of the FNR is as shown in SEQ ID NO: 1, or h...
|
|
WO/2024/089663A1 |
The present disclosure relates to a method and a composition for the treatment/prevention of neurodegenerative diseases, in particular Machado-Joseph disease (MJD)/ Spinocerebellar Ataxia type-3 (SCA3) by utilizing extracellular vesicles...
|
|
WO/2024/088404A1 |
This disclosure provides engineered 4-1BBL variants, and methods of use thereof.
|
|
WO/2024/087405A1 |
A Cas mutant protein. Compared with a parent Cas protein, the Cas mutant protein has a significantly improved editing activity and broad application prospects.
|
|
WO/2024/090413A1 |
The present invention addresses the problem of providing a lactic acid bacterium having high natural immunoactivating capability. The present invention also addresses the problem of providing: a natural immunoactivator which contains, as...
|
|
WO/2024/088372A1 |
A method for efficiently and rapidly obtaining stable apple transgenic plants by using Agrobacterium rhizogenes. In the method, apple leaves are used as receptors to obtain adventitious buds instead of hairy roots through the mediation o...
|
|
WO/2024/090440A1 |
It was discovered that, by using (a) FDC in which position 397 is tryptophan, position 398 is methionine, position 440 is tyrosine, and position 189 is methionine and/or (b) FDC in which position 397 is tryptophan, position 398 is methio...
|
|
WO/2024/089639A1 |
The disclosure provides, at least in part, formulation buffers suitable for lentiviral vectors.
|
|
WO/2024/091417A1 |
Human hyaluronidase 1 (HYAL1) mutants that are highly expressed and display hyaluronidase activity from pH 3.5 to pH 5.5 are disclosed.
|
|
WO/2024/092105A2 |
The present disclosure relates to RNAi agents, e.g., double stranded RNAi agents or siRNAs, able to inhibit Complement Component C3 (C3) gene expression. Also disclosed are pharmaceutical compositions that include C3 RNAi agents and meth...
|
|
WO/2024/091058A1 |
The present invention relates to a cell panning method, a vector used in the method, and transformed cells used in the method. According to the cell panning method according to the present invention, an antibody having a binding ability ...
|
|
WO/2024/090883A1 |
The present invention relates to a pyruvate kinase 2 novel variant and a method for producing an L-aromatic amino acid using same. The pyruvate kinase 2 variant has protein activity that is altered by substitution of one or more amino ac...
|
|
WO/2024/092120A2 |
siRNA molecules and pharmaceutical compositions containing siRNA molecules are provided for inhibiting expression of KRAS, RAF1 and mutant KRAS peptides or proteins. Methods of treatment of cancer are provided in which the pharmaceutical...
|
|
WO/2024/006460A9 |
Biomarkers and machine learning techniques to identify biomarkers are disclosed herein. In one particular implementation, the present disclosure relates to the identification of biomarkers to be used in the detection and diagnosis of LD....
|
|
WO/2024/090885A1 |
The present invention relates to a novel variant of the DNA-binding transcriptional regulator MalT and a method for producing an L-aromatic amino acid using same. The variant of the DNA-binding transcriptional regulator MalT has protein ...
|
|
WO/2024/089671A1 |
The present invention discloses a fusion protein SEQ ID NO: 1, comprising dodecin and Flavin Binding Fluorescent Protein (FBFP) for sequestering riboflavin to prevent the formation of skunk beer. The invention discloses the process of co...
|
|
WO/2024/087070A1 |
The present application relates to the technical field of biology, and specifically relates to a plasmid target, primer probe, kit and method for detecting residual host cell DNA in a cellular preparation or viral preparation. The plasmi...
|
|
WO/2024/087267A1 |
Provided is a chimeric antigen receptor capable of identifying and binding to TGFβRII. The chimeric antigen receptor is used in combination with a chimeric antigen receptor capable of identifying and binding to a tumor-specific antigen ...
|
|
WO/2024/089953A1 |
The present invention provides a method for producing oligonucleotide by a solid-phase synthesis technique, wherein said method for producing oligonucleotide comprises a step for reacting, in the presence of a thiol, an acid with an olig...
|
|
WO/2024/092171A1 |
The disclosure provides a method to assemble up to four viral, e.g., adeno- associated virus (AAV), genomes in vivo in a pre-designed configuration using a DNA recombination system to provide delivery of large genes that exceed the AAV' ...
|
|
WO/2024/092249A2 |
Provided herein is the identification of markers and genes associated with flower initiation in Cannabis. The markers are useful for breeding Cannabis plants that initiate flowering at longer daylightsdaylengths, which allows for earlier...
|
|
WO/2024/092248A1 |
Disclosed herein include light gated potassium selective channelrhodopsins (KCRs). Various embodiments include a KCR comprising an amino acid substitution that alters a property of the KCR. Certain embodiments are derived from a natural ...
|
